Developer docs
API playgroundTry for free, no card

Search company profiles

MediWound

Full company profile

uuid0000i76

Namestring
MediWound
Legal namestring
MediWound Ltd.
Websiteurl
mediwound.com
Company typeenum
Public
Founded yearint
2001
Descriptiontext

MediWound Ltd. is a fully integrated biotechnology company founded in 2001 and headquartered in Yavne, Israel, listed on NASDAQ under the ticker MDWD. It develops and commercializes next-generation enzymatic therapies for non-surgical tissue repair, focused on two products built on a proprietary bromelain-based platform derived from pineapple plant stems. NexoBrid, an FDA-, EMA-, and PMDA-approved orphan biological drug, selectively removes eschar in deep partial- and full-thickness thermal burns for adult and pediatric patients and is marketed in over 40 countries. EscharEx, the second platform product, is a bioactive enzymatic therapy in Phase III development for debridement of chronic and hard-to-heal wounds (venous leg ulcers, diabetic foot ulcers, pressure ulcers).

The company operates a vertically integrated model spanning R&D, cGMP-certified aseptic manufacturing (recently expanded to sixfold prior capacity), and global commercialization. In the United States, NexoBrid is sold through an exclusive partnership with Vericel Corporation, which also holds the BARDA procurement contract. In Europe, MediWound runs direct sales supplemented by PolyMedics Innovations for the DACH region, with additional distribution partners in Japan and Australia. The revenue mix blends commercial product sales with substantial non-dilutive funding: a BARDA contract worth up to $197 million over ten years, $14.4 million in cumulative U.S. Department of Defense funding for a temperature-stable military formulation, and a €16.25 million European Innovation Council award supporting EscharEx development.

Management is led by CEO Ofer Gonen (former CEO of Clal Biotechnology Industries), with a board chaired by Nachum Shamir (former CEO of Given Imaging and Luminex). MediWound has treated over 16,000 patients worldwide and operates from offices in Israel, Germany, the United States, and five additional European countries. FY2025 revenue was $17.0 million, down from $20.2 million in 2024 due to U.S. government procurement delays, while management guides to $24–26 million in 2026 and $50–55 million by 2028.

Short descriptiontext

MediWound is a commercial and clinical-stage biotechnology company developing bromelain-based enzymatic therapies for non-surgical burn and chronic wound debridement. Its approved product NexoBrid is marketed in over 40 countries, while EscharEx is in Phase III development for chronic wounds.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersYavne, Israel
HQ citystring
Yavne
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
enzymatic debridement therapy, burn wound care, chronic wound treatment, biological therapeutics, tissue repair drugs
Industry3 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAKACAN
Wound Care & Ulcer Management
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Enzymatic Wound Care Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales (NexoBrid)
TypeOne Time License
Description

Revenue generated from sales of FDA/EMA/PMDA approved NexoBrid for burn eschar removal, marketed in over 40 countries through direct sales and distribution partnerships.

globenewswire.com
2Government Contracts (BARDA/DoD)
TypeLicensing Royalties
Description

Non-dilutive funding from U.S. government agencies including BARDA contract worth up to $197 million for NexoBrid procurement and development, and DoD funding for temperature-stable formulation development ($18.2 million disclosed for room-temperature stable formulation).

stocktitan.net
3European Innovation Council Funding
TypeProfessional Services
Description

€16.25 million funding from EIC to support EscharEx development for diabetic foot ulcers, including €2.5 million grant component, aimed at accelerating market introduction by four years.

ir.mediwound.com
4Strategic Partnership Revenue
TypeLicensing Royalties
Description

$25 million private placement financing from Mölnlycke Health Care to fund development and commercialization activities, strengthening strategic partnership in wound care solutions.

ir.mediwound.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1NexoBrid
Description

FDA, EMA and PMDA approved orphan biological drug for eschar removal in deep partial and full-thickness thermal burns for adults and pediatric patients

mediwound.com
+1 more record
Core offering1 text field

MediWound develops and commercializes proprietary bromelain-based enzymatic therapeutics for non-surgical tissue repair. Its commercial product NexoBrid is an FDA, EMA, and PMDA approved orphan biological drug for enzymatic eschar removal in deep partial and full-thickness thermal burns, marketed in over 40 countries. Its pipeline product EscharEx is a Phase III bioactive enzymatic therapy for debridement of chronic, hard-to-heal wounds including venous leg ulcers, diabetic foot ulcers, and pressure ulcers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 16,000 patients treated worldwide with NexoBrid
+3 more records
Product overview1 text field

MediWound is a fully integrated biotechnology company developing next-generation enzymatic therapeutics for non-surgical tissue repair. The company operates two core products: NexoBrid®, an FDA/EMA/PMDA approved orphan biologic for burn eschar removal currently marketed in over 40 countries, and EscharEx®, a Phase III pipeline drug for chronic wound debridement targeting venous leg ulcers, diabetic foot ulcers, and pressure ulcers. Both products are based on a proprietary platform technology using proteolytic enzymes enriched in bromelain derived from pineapple plant stems. The company maintains vertically integrated capabilities spanning R&D, manufacturing (cGMP-certified facility), and global commercialization through partnerships.

Product and service2 records
1NexoBrid
CategoryApproved Biologic Drug
Description

FDA, EMA, and PMDA approved orphan biological drug for enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. Selectively removes non-viable tissue while preserving viable tissue. Approved for use in adults and pediatric patients in over 40 countries including the United States, European Union, and Japan.

2EscharEx
CategoryPipeline Biologic Drug (Phase III)
Description

Bromelain-based, bioactive enzymatic therapy in advanced clinical development for debridement of chronic and hard-to-heal wounds. Designed for topical, once-daily application with demonstrated favorable safety profile and effective wound bed preparation in multiple Phase II trials. Global Phase III study in venous leg ulcers underway; DFU trial planned for H2 2026; PU IIT planned for H2 2026.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

B. Braun joined MediWound's clinical development program as research collaborator for diabetic foot ulcer (DFU) study, supporting Phase II clinical trial preparation planned for H2 2026.

Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-01
Description

November 2024 partnership to expand NexoBrid distribution across Europe. PolyMedics serves as promotional partner in DACH region while supporting broader European market access.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Strategic partnership for U.S. commercialization of NexoBrid. Vericel holds BARDA contract for government procurement and development activities. Company markets NexoBrid in the United States for burn eschar removal.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers9 records
TypeDirect peer
Description

Vericel is MediWound's US commercialization partner for NexoBrid and holds the BARDA stockpile contract. Vericel also commercializes MACI and Epicel in the regenerative medicine space, making it both a commercial partner and a strategic comparable in cell-based and biologic wound/orthopedic therapies.

TypeBroad incumbent
Description

Mölnlycke is a global leader in advanced wound care (Mepilex, Mepitel) and made a $25M strategic investment in MediWound. As a major incumbent in the same wound care end-market, Mölnlycke represents both a partner and a benchmark for scaled wound care commercialization.

TypeBroad incumbent
Description

Smith & Nephew's Advanced Wound Management portfolio competes with NexoBrid/EscharEx in the broader wound debridement and healing space. As a large diversified medtech incumbent, it represents the scale benchmark MediWound aims to compete against as it expands into chronic wound indications.

TypeBroad incumbent
Description

Integra LifeSciences acquired Derma Sciences in 2017 and competes directly in advanced wound care with skin substitutes and regenerative products. MediWound board member Stephen Wills previously served as Executive Chairman of Derma Sciences, highlighting direct competitive and personnel overlap.

TypeBroad incumbent
Description

ConvaTec is a major global wound care company offering advanced dressings, hydrocolloids, and debridement products across chronic and acute wound markets. It is a key incumbent peer for MediWound's planned expansion into diabetic foot ulcers and venous leg ulcers with EscharEx.

TypeDirect peer
Description

Organogenesis is a regenerative medicine company specializing in skin substitutes and wound care biologics (Apligraf, Dermagraft). It competes directly with MediWound's bromelain enzymatic platform in the chronic wound healing market, particularly for venous leg ulcers and diabetic foot ulcers.

TypeDirect peer
Description

MiMedx develops and commercializes regenerative biologics (EpiFix, AmnioFix) for wound care and surgical recovery. It competes with NexoBrid and EscharEx in the advanced wound care biologics space and serves similar hospital and outpatient wound care channels.

TypeBroad incumbent
Description

Coloplast's Wound & Skin Care division offers a broad portfolio of dressings and wound management products across chronic wound indications including DFUs and VLUs. As a European medtech incumbent with similar chronic wound focus, it represents a relevant commercial benchmark for MediWound's EscharEx pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MediWound

Enzymatic Wound Care Therapeuticsmediwound.com

MediWound is a commercial and clinical-stage biotechnology company developing bromelain-based enzymatic therapies for non-surgical burn and chronic wound debridement. Its approved product NexoBrid is marketed in over 40 countries, while EscharEx is in Phase III development for chronic wounds.

What MediWound does

MediWound Ltd. is a fully integrated biotechnology company founded in 2001 and headquartered in Yavne, Israel, listed on NASDAQ under the ticker MDWD. It develops and commercializes next-generation enzymatic therapies for non-surgical tissue repair, focused on two products built on a proprietary bromelain-based platform derived from pineapple plant stems. NexoBrid, an FDA-, EMA-, and PMDA-approved orphan biological drug, selectively removes eschar in deep partial- and full-thickness thermal burns for adult and pediatric patients and is marketed in over 40 countries. EscharEx, the second platform product, is a bioactive enzymatic therapy in Phase III development for debridement of chronic and hard-to-heal wounds (venous leg ulcers, diabetic foot ulcers, pressure ulcers).

The company operates a vertically integrated model spanning R&D, cGMP-certified aseptic manufacturing (recently expanded to sixfold prior capacity), and global commercialization. In the United States, NexoBrid is sold through an exclusive partnership with Vericel Corporation, which also holds the BARDA procurement contract. In Europe, MediWound runs direct sales supplemented by PolyMedics Innovations for the DACH region, with additional distribution partners in Japan and Australia. The revenue mix blends commercial product sales with substantial non-dilutive funding: a BARDA contract worth up to $197 million over ten years, $14.4 million in cumulative U.S. Department of Defense funding for a temperature-stable military formulation, and a €16.25 million European Innovation Council award supporting EscharEx development.

Management is led by CEO Ofer Gonen (former CEO of Clal Biotechnology Industries), with a board chaired by Nachum Shamir (former CEO of Given Imaging and Luminex). MediWound has treated over 16,000 patients worldwide and operates from offices in Israel, Germany, the United States, and five additional European countries. FY2025 revenue was $17.0 million, down from $20.2 million in 2024 due to U.S. government procurement delays, while management guides to $24–26 million in 2026 and $50–55 million by 2028.

MediWound firmographics

Firmographics
Name
MediWound
Legal name
MediWound Ltd.
Website
https://mediwound.com
Company type
Public
Founded year
2001
Operating status
Operating
Headcount range
101–250 employees
Short description
MediWound is a commercial and clinical-stage biotechnology company developing bromelain-based enzymatic therapies for non-surgical burn and chronic wound debridement. Its approved product NexoBrid is marketed in over 40 countries, while EscharEx is in Phase III development for chronic wounds.
Ownership category
akta.pro rank

MediWound industry classification

Industry
Product category
Enzymatic Wound Care Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAKACAN
Wound Care & Ulcer Management

Keywords

  • Enzymatic debridement therapy
  • Burn wound care
  • Chronic wound treatment
  • Biological therapeutics
  • Tissue repair drugs

Where MediWound is headquartered

Location

Headquarters

HQ city
Yavne
HQ country
Israel
HQ region
Middle East

Offices8 records

Markets served

MediWound business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Product Sales (NexoBrid): Revenue generated from sales of FDA/EMA/PMDA approved NexoBrid for burn eschar removal, marketed in over 40 countries through direct sales and distribution partnerships.
  2. Government Contracts (BARDA/DoD): Non-dilutive funding from U.S. government agencies including BARDA contract worth up to $197 million for NexoBrid procurement and development, and DoD funding for temperature-stable formulation development ($18.2 million disclosed for room-temperature stable formulation).
  3. European Innovation Council Funding: €16.25 million funding from EIC to support EscharEx development for diabetic foot ulcers, including €2.5 million grant component, aimed at accelerating market introduction by four years.
  4. Strategic Partnership Revenue: $25 million private placement financing from Mölnlycke Health Care to fund development and commercialization activities, strengthening strategic partnership in wound care solutions.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

MediWound product offering

Product offering

Core offering

MediWound develops and commercializes proprietary bromelain-based enzymatic therapeutics for non-surgical tissue repair. Its commercial product NexoBrid is an FDA, EMA, and PMDA approved orphan biological drug for enzymatic eschar removal in deep partial and full-thickness thermal burns, marketed in over 40 countries. Its pipeline product EscharEx is a Phase III bioactive enzymatic therapy for debridement of chronic, hard-to-heal wounds including venous leg ulcers, diabetic foot ulcers, and pressure ulcers.

Product overview

MediWound is a fully integrated biotechnology company developing next-generation enzymatic therapeutics for non-surgical tissue repair. The company operates two core products: NexoBrid®, an FDA/EMA/PMDA approved orphan biologic for burn eschar removal currently marketed in over 40 countries, and EscharEx®, a Phase III pipeline drug for chronic wound debridement targeting venous leg ulcers, diabetic foot ulcers, and pressure ulcers. Both products are based on a proprietary platform technology using proteolytic enzymes enriched in bromelain derived from pineapple plant stems. The company maintains vertically integrated capabilities spanning R&D, manufacturing (cGMP-certified facility), and global commercialization through partnerships.

Differentiator

Problem solved

Functional benefit

Brands

  • NexoBrid: FDA, EMA and PMDA approved orphan biological drug for eschar removal in deep partial and full-thickness thermal burns for adults and pediatric patients
  • EscharEx

Products and services

  • NexoBrid FDA, EMA, and PMDA approved orphan biological drug for enzymatic removal of eschar in patients with deep partial- and full-thickness thermal burns. Selectively removes non-viable tissue while preserving viable tissue. Approved for use in adults and pediatric patients in over 40 countries including the United States, European Union, and Japan.
  • EscharEx Bromelain-based, bioactive enzymatic therapy in advanced clinical development for debridement of chronic and hard-to-heal wounds. Designed for topical, once-daily application with demonstrated favorable safety profile and effective wound bed preparation in multiple Phase II trials. Global Phase III study in venous leg ulcers underway; DFU trial planned for H2 2026; PU IIT planned for H2 2026.

Quantifiable outcome

  • Over 16,000 patients treated worldwide with NexoBrid
  • +3 more outcomes

Companies that use MediWound

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

MediWound technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

MediWound partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor, strategic and core.

  • B. BraunminorStrategic or Co-development Partner · 1 January 2025B. Braun joined MediWound's clinical development program as research collaborator for diabetic foot ulcer (DFU) study, supporting Phase II clinical trial preparation planned for H2 2026.
  • PolyMedics Innovations GmbHstrategicChannel Partner/ Reseller/ Distributor · 1 November 2024November 2024 partnership to expand NexoBrid distribution across Europe. PolyMedics serves as promotional partner in DACH region while supporting broader European market access.
  • Vericel CorporationcoreChannel Partner/ Reseller/ DistributorStrategic partnership for U.S. commercialization of NexoBrid. Vericel holds BARDA contract for government procurement and development activities. Company markets NexoBrid in the United States for burn eschar removal.

Scale indicators16 records

Recent moves6 records

Expansion highlights6 records

MediWound competitors and assessment

Company assessment

Direct peers

  • Vericel Corporation: Vericel is MediWound's US commercialization partner for NexoBrid and holds the BARDA stockpile contract. Vericel also commercializes MACI and Epicel in the regenerative medicine space, making it both a commercial partner and a strategic comparable in cell-based and biologic wound/orthopedic therapies.
  • Organogenesis Holdings: Organogenesis is a regenerative medicine company specializing in skin substitutes and wound care biologics (Apligraf, Dermagraft). It competes directly with MediWound's bromelain enzymatic platform in the chronic wound healing market, particularly for venous leg ulcers and diabetic foot ulcers.
  • MiMedx Group: MiMedx develops and commercializes regenerative biologics (EpiFix, AmnioFix) for wound care and surgical recovery. It competes with NexoBrid and EscharEx in the advanced wound care biologics space and serves similar hospital and outpatient wound care channels.

Broad incumbents

  • Mölnlycke Health Care: Mölnlycke is a global leader in advanced wound care (Mepilex, Mepitel) and made a $25M strategic investment in MediWound. As a major incumbent in the same wound care end-market, Mölnlycke represents both a partner and a benchmark for scaled wound care commercialization.
  • Smith & Nephew: Smith & Nephew's Advanced Wound Management portfolio competes with NexoBrid/EscharEx in the broader wound debridement and healing space. As a large diversified medtech incumbent, it represents the scale benchmark MediWound aims to compete against as it expands into chronic wound indications.
  • Integra LifeSciences: Integra LifeSciences acquired Derma Sciences in 2017 and competes directly in advanced wound care with skin substitutes and regenerative products. MediWound board member Stephen Wills previously served as Executive Chairman of Derma Sciences, highlighting direct competitive and personnel overlap.
  • ConvaTec Group: ConvaTec is a major global wound care company offering advanced dressings, hydrocolloids, and debridement products across chronic and acute wound markets. It is a key incumbent peer for MediWound's planned expansion into diabetic foot ulcers and venous leg ulcers with EscharEx.
  • Coloplast: Coloplast's Wound & Skin Care division offers a broad portfolio of dressings and wound management products across chronic wound indications including DFUs and VLUs. As a European medtech incumbent with similar chronic wound focus, it represents a relevant commercial benchmark for MediWound's EscharEx pipeline.

Peers

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

MediWound social profiles

Digital presence

MediWound compliance and trust

Trust signal

Compliance4 records

MediWound financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MediWound leadership team

Management profile

Number of profiles

Profiles16 records

MediWound funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MediWound M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MediWound

What does MediWound do?

MediWound develops and commercializes proprietary bromelain-based enzymatic therapeutics for non-surgical tissue repair. Its commercial product NexoBrid is an FDA, EMA, and PMDA approved orphan biological drug for enzymatic eschar removal in deep partial and full-thickness thermal burns, marketed in over 40 countries. Its pipeline product EscharEx is a Phase III bioactive enzymatic therapy for debridement of chronic, hard-to-heal wounds including venous leg ulcers, diabetic foot ulcers, and pressure ulcers.

Is MediWound a public or private company?

MediWound is a public company. It is classified as public and is currently operating.

When was MediWound founded?

MediWound was founded in 2001. It employs 101 to 250 people.

Where is MediWound based?

MediWound is headquartered in Yavne, Israel, in the Middle East region.

How does MediWound make money?

Four revenue lines are on record. Product Sales (NexoBrid) is the primary driver. The others are government Contracts (BARDA/DoD), european Innovation Council Funding and strategic Partnership Revenue.

Who are MediWound's main competitors?

Direct peers on record are Vericel Corporation, Organogenesis Holdings and MiMedx Group. Broad incumbents are Mölnlycke Health Care, Smith & Nephew, Integra LifeSciences, ConvaTec Group and Coloplast. PolyMedics Innovations (PMI) is listed as a peer.

Does MediWound have an API?

No public API is recorded for MediWound.

What industry is MediWound in?

MediWound's product category is Enzymatic Wound Care Therapeutics. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestegateMediWound’s CEO and Chairman Increase Their Holdings as a Pivotal Trial Milestone Nears (NASDAQ: MDWD)MediWound's CEO, chairman, and a director exercised warrants to acquire 31,038 ordinary shares for $418,237. NexoBrid commercial revenue reached $5.3 million, and the Phase 3 VALUE trial for EscharEx is expected to complete enrollment by Q1 2027.Simply Wall StMediWound Ltd. (NASDAQ:MDWD) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMediWound's shares fell 9.5% after quarterly results showed revenue 47% below estimates, though losses were 35% smaller than predicted. Analysts cut 2027 revenue forecasts to $29.2m from $31.8m, with no change to the $29.67 price target. The company is expected to grow faster than the industry, but analysts see no major shift in valuation.The Motley FoolMediWound (MDWD) Q3 2026 Earnings Call TranscriptMediWound reported Q3 2026 revenue of $3.6 million and a net loss of $6 million, driven by lower U.S. government development services revenue and higher clinical trial spending. The company expects to complete enrollment in its EscharEx Phase III VALUE trial by the end of Q1 2027, with top-line results anticipated in mid-2027.The Motley FoolMediWound (MDWD) Q3 2026 Earnings Call TranscriptMediWound reported Q3 2026 revenue of $3.6 million and a net loss of $6 million, driven by lower U.S. government development services and higher clinical trial spending. The company expects to complete the EscharEx Phase III VALUE trial enrollment by the end of Q1 2027, with top-line results anticipated in mid-2027.MarketScreenerMediWound Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026MediWound Ltd. reported Q3 2026 sales of $3.57 million and a net loss of $5.99 million, down from $5.43 million and $2.65 million respectively. For the nine months, sales fell to $8.14 million from $15.09 million, and net loss narrowed to $16.33 million from $16.7 million.Quiver QuantitativeMEDIWOUND ($MDWD) Releases Q3 2026 Earnings | MDWD Stock NewsMEDIWOUND reported Q3 2026 earnings of -$0.65 per share, beating estimates of -$0.72, but revenue of $3.57M missed estimates of $6.86M. Insiders made 7 purchases and 1 sale in the past six months, while 37 institutional investors added shares and 33 reduced positions.Business & FinancialMediwound's Burn Drug Is Gaining Speed. Its Next Target Could Be Much Bigger (NASDAQ: MDWD)MediWound's burn drug NexoBrid saw record commercial sales and federal procurement revenue, with Vericel reporting $2.3 million in commercial revenue and $3 million in procurement. The company is advancing its chronic-wound candidate EscharEx in Phase 3, with an estimated U.S. annual peak sales potential of $1.05 billion.Seeking AlphaMediWound announces $15M public offering of ordinary shares (MDWD:NASDAQ)MediWound entered an underwriting agreement with H.C. Wainwright & Co. for a firm-commitment public offering of 1.2 million ordinary shares at $12.50 per share, expecting to raise about $15 million in gross proceeds. The company granted a 30-day option to buy an additional 180,000 shares, and the offering is expected to close on or around November 5, 2026.TradingViewMediWound (MDWD) Announces $15M Share OfferingMediWound agreed to sell 1.2 million ordinary shares at $12.50 each, raising approximately $15 million in gross proceeds before discounts and expenses. The offering includes a 30-day option for up to 180,000 additional shares, with closing expected on or about November 5, 2026, subject to customary conditions.InvestegateMediWound’s EscharEx Strategy May Be Ahead of the Game as FDA Puts Chronic Wounds in Focus (Nasdaq: MDWD)MediWound's Phase 3 EscharEx trial tests enzymatic debridement for chronic wounds, with co-primary endpoints of complete debridement and facilitation of wound closure. The FDA's August 25 meeting focused on chronic wound patient experiences, and the company expects enrollment completion by Q1 2027.